Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial

References

• Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–887.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin–angiotensin system. Drugs. 2004; 64:2537–2565.
   PubMed Web of Science ®Google Scholar
• Ostergren J. Renin–angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract. 2007;76 Suppl 1:S13–S21.
   PubMed Web of Science ®Google Scholar
• Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699–1707.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002;40:609–611.
   PubMed Web of Science ®Google Scholar
• Sharpe M, Jarvis B, Goa KL. Telmisartan: A review of its use in hypertension. Drugs. 2001;61:1501–1529.
   PubMed Web of Science ®Google Scholar
• Kurtz TW. Treating the metabolic syndrome: Telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005;42 Suppl 1:S9–S16.
   PubMed Web of Science ®Google Scholar
• Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: Does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer?Diabetologia. 2007;50:1127–1139.
   PubMed Web of Science ®Google Scholar
• , DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsGerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet. 2006;368:1096–1105.
   PubMed Web of Science ®Google Scholar
• Nagel JM, Tietz AB, Göke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55: 1149–1154.
   PubMed Web of Science ®Google Scholar
• Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest. 2006;29:957–961.
   PubMed Web of Science ®Google Scholar
• Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55:1159–1164.
   PubMed Web of Science ®Google Scholar
• Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther. 2007;24:146–153.
   PubMed Web of Science ®Google Scholar
• Inoue T, Morooka T, Moroe K, Ikeda H, Node K. Effect of telmisartan on cholesterol levels in patients with hypertension – Saga Telmisartan Aggressive Research (STAR). Horm Metab Res. 2007;39:372–376.
   PubMed Web of Science ®Google Scholar
• Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism. 2008;57:1473–1478.
   PubMed Web of Science ®Google Scholar
• Komiya N, Hirose H, Kawabe H, Itoh H, Saito I. Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity. J Atheroscler Thromb. 2009;16:137–142.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary, National Institutes of Health NIH Publication No. 01–3670, May. 2001.
   Google Scholar
• Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. Revision. 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association Circulation. 2000;102:2284.
   Google Scholar
• Li X, Youngren JF, Hyun B, Sakkas GK, Mulligan K, Majumdar S, et al. Technical evaluation of in vivo abdominal fat and IMCL quantification using MRI and MRSI at 3 T. Magn Reson Imaging. 2008;26:188–197.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab. 2003;17:305–322.
   PubMed Web of Science ®Google Scholar
• Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Marc P, Teboul M. Angiotensinogen, angiotensin II, and adipose tissue development, Int J Obes Relat Metab Disord. 2000;24:S33–S35.
   Google Scholar
• Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699–1707.
   PubMed Web of Science ®Google Scholar
• Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes.1999;48:1113–1119.
   PubMed Web of Science ®Google Scholar
• Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Halavaara J, et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes. 2001;50:2337–2343.
   PubMed Web of Science ®Google Scholar
• Gavrilova O, Mareus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al.Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice, J Clin Invest. 2000;105:271–278.
   Google Scholar
• Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947–953.
   PubMed Web of Science ®Google Scholar
• Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein DH, Smith SA, et al. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: An in vivo nuclear magnetic resonance study. Metabolism. 2003;52:218–225.
   PubMed Web of Science ®Google Scholar
• Hsueh W, Davidai G, Henry R, Mudaliar S. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens. 2010;12:746–752.
   Web of Science ®Google Scholar
• Barzilay JI, Gao P, Rydén L, Schumacher H, Probstfield J, Commerford P, et al.; TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND study. Diabetes Care. 2011;34:1902–1907.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res. 2009;41:893–898.
   PubMed Web of Science ®Google Scholar
• Lua T, Carlsson PO, Leung PS. Evidence of a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia. 2004;47:240–248.
   PubMed Web of Science ®Google Scholar
• Bonora E. Protection of pancreatic beta-cells: Is it feasible?Nutr Metab Cardiovasc Dis. 2008;18:74–83.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ura N, Higashiura K, Murakami H, Shimamoto K. Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76–81.
   PubMed Web of Science ®Google Scholar
• Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: A meta-analysis of randomized head-to-head trials. Int J Cardiol. 2012;156:92–96.
   PubMed Web of Science ®Google Scholar